Stryker Target of Unusually High Options Trading (NYSE:SYK)

Stryker Corporation (NYSE:SYK) saw some unusual options trading activity on Thursday. Stock traders acquired 3,175 call options on the company. This is an increase of approximately 104% compared to the typical volume of 1,553 call options.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. VanderPol Investments L.L.C. increased its position in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC boosted its holdings in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC boosted its holdings in shares of Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC grew its stake in shares of Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after buying an additional 29 shares during the period. Finally, Sompo Asset Management Co. Ltd. grew its stake in shares of Stryker by 1.3% during the 2nd quarter. Sompo Asset Management Co. Ltd. now owns 2,390 shares of the medical technology company’s stock valued at $946,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK traded up $17.83 during midday trading on Thursday, hitting $334.27. The stock had a trading volume of 506,346 shares, compared to its average volume of 2,362,599. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $311.28 and a 200-day simple moving average of $337.10. The company has a market capitalization of $128.15 billion, a PE ratio of 38.63, a P/E/G ratio of 1.99 and a beta of 0.77. Stryker has a 1 year low of $281.00 and a 1 year high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, sell-side analysts expect that Stryker will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Wall Street Analyst Weigh In

Several analysts have commented on SYK shares. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Robert W. Baird set a $385.00 target price on Stryker in a research report on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, BMO Capital Markets initiated coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.